Chemotherapy Dosing Part II: Alternative Approaches and Future Prospects

Clinical Oncology

Volumn 19, Issue 2, 2007, Pages 99-107

  Kaestner, S A ^a   Sewell, G J ^b  

^a University of Bath   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Body surface area; cancer; chemotherapy; dose; pharmacokinetics

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EDETATE CHROMIUM CR 51; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; INULIN; IOHEXOL; IOTALAMIC ACID I 125; IRINOTECAN; MAGNESIUM; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PENTETATE TECHNETIUM TC 99M; POTASSIUM; PRODRUG; SURAMIN; THIOTEPA;

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MEGADOSE; DRUG MONITORING; ENZYME ACTIVITY; HUMAN; MEDICATION ERROR; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 33846691570     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.10.003     Document Type: Article

References (114)

1. Kaestner SA, Sewell GJ. Chemotherapy dosing part I: scientific basis for current practice and use of body surface area (BSA). Clin Oncol 2006;19.
2. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 (1989) 1748-1756
3. Ghazal-Aswad S., Calvert A.H., and Newell D.R. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 37 (1996) 429-434
4. Allsopp M.A., and Sewell G.J. A pharmacokinetic-pharmacodynamic study on carboplatin administered in prolonged continuous infusion regimens with synchronous radiotherapy. J Oncol Pharm Pract 1 (1995) 25-32
5. Duffull S.B., and Robinson B.A. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33 (1997) 161-183
6. Calvert A.H., Harland S.J., Newell D.R., Siddik Z.H., and Harrap K.R. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 12 Suppl A (1985) 51-57
7. Huitema A.D.R., Mathot R.A.A., Tibben M.M., Schellens J.H.M., Rodenhuis S., and Beijnen J.H. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther 67 (2000) 621-630
8. Egorin M.J., Van Echo D.A., Tipping S.J., et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44 (1984) 5432-5438
9. Egorin M.J., Van Echo D.A., Olman E.A., Whitacre M.Y., Forrest A., and Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 45 (1985) 6502-6506
10. Jodrell D.I., Egorin M.J., Canetta R.M., et al. Relationships between carboplatin exposure and tumour response and toxicity in patients with ovarian cancer. J Clin Oncol 10 (1992) 520-528
11. Harland S.J., Newell D.R., Siddik Z.H., Chadwick R., Calvert A.H., and Harrap K.R. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 44 (1984) 1693-1697
12. Calvert H., Judson I., and van der Vijgh W.J.F. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv 17 (1993) 189-217
13. Sørensen B.T., Strömgren A., Jakobsen P., Nielsen J.T., Smedegaard Andersen L., and Jakobsen A. Renal handling of carboplatin. Cancer Chemother Pharmacol 30 (1992) 317-320
14. van Warmerdam L.J.C., Rodenhuis S., ten Bokkel Huinink W.W., Maes R.A.A., and Beijnen J.H. The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 121 (1995) 478-486
15. Jeyabalan N., Hirte H.W., and Moens F. Treatment of advanced ovarian carcinoma with carboplatin in a patient with renal failure. Int J Gynecol Cancer 10 (2000) 463-468
16. de Jonge M.E., Huitema A.D.R., Tukker A.C., van Dam S.M., Rodenhuis S., and Beijnen J.H. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Clin Cancer Res 11 (2005) 273-283
17. de Jonge M.E., van den Bongard H.J.G.D., Huitema A.D.R., et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 10 (2004) 2237-2244
18. Millward M.J., Webster L.K., Toner G.C., et al. Carboplatin dosing based on measurement of renal function - experience at the Peter MacCallum Cancer Institute. Aust N Z J Med 26 (1996) 372-379
19. van Warmerdam L.J.C., Rodenhuis S., van der Wall E., Maes R.A.A., and Beijnen J.H. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer 73 (1996) 979-984
20. Calvert A.H. Dose optimisation of carboplatin in adults. Anticancer Res 14 (1994) 2273-2278
21. Rowland M., and Tozer T.N. Clinical pharmacokinetics, concepts and applications (1995), Lippincott Williams and Wilkins, Philadelphia
22. Payne R.B. Creatinine clearance and glomerular filtration rate. Ann Clin Biochem 37 (2000) 98-99
23. Bostom A.G., Kronenberg F., and Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 13 (2002) 2140-2144
24. Murray P.T., and Ratain M.J. Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs. J Clin Oncol 21 (2003) 2633-2635
25. Keir M.J., Morris K.P., and Skinner R. The direct measurement of glomerular filtration rate from the continuous monitoring of DTPA clearance. Physiol Meas 14 (1993) 71-78
26. Levey A.S., Greene T., Schluchter M.D., et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 4 (1993) 1159-1171
27. van Warmerdam L.J., Rodenhuis S., ten Bokkel Huinink W.W., Maes R.A.A., and Beijnen J.H. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 37 (1996) 266-270
28. Ando M., Minami H., Ando Y., et al. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 6 (2000) 4733-4738
29. van den Bongard H.J.G.D., Mathôt R.A.A., Beijnen J.H., and Schellens J.H.M. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 39 (2000) 345-367
30. Alberts D.S., and Dorr R.T. New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumours. Oncologist 3 (1998) 15-34
31. Chatelut E., Canal P., Brunner V., et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87 (1995) 573-580
32. Dowling T.C., Frye R.F., Fraley D.S., and Matzke G.R. Comparison of iothalamate clearance methods for measuring GFR. Pharmacotherapy 19 (1999) 943-950
33. Wright J.G., Calvert A.H., Highley M.S., et al. Accurate prediction of renal function for carboplatin dosing. Proc Am Assoc Cancer Res 40 (1999) 384
34. Itoh K. Comparison of methods for determination of glomerular filtration rate: Tc-99m-DTPA renography, predicted creatinine clearance method and plasma sample method. Ann Nucl Med 17 (2003) 561-565
35. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130 (1999) 461-470
36. Marx G.M., Blake G.M., Galani E., et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 15 (2004) 291-295
37. Wright J.G., Boddy A.V., Highley M., Fenwick J., McGill A., and Calvert A.H. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84 (2001) 452-459
38. Lewis J., Agodoa L., Cheek D.-A., et al. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis 38 (2001) 744-753
39. Dooley M.J., Poole S.G., Rischin D., and Webster L.K. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 38 (2002) 44-51
40. Filler G., Foster J., Acker A., Lepage N., Akbari A., and Ehrich J.H.H. The Cockroft-Gault formula should not be used in children. Kidney Int 67 (2005) 2321-2324
41. Beddhu S., Samore M.H., Roberts M.S., Stoddard G.J., Pappas L.M., and Cheung A.K. Creatinine production, nutrition, and glomerular filtration rate estimation. J Am Soc Nephrol 14 (2003) 1000-1005
42. Rule A.D., Larson T.S., Bergstralh E.J., Slezak J.M., Jacobsen S.J., and Cosio F.G. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and chronic kidney disease. Ann Intern Med 141 (2004) 929-937
43. Herrington J.D., Tran H.T., and Riggs M.W. Prospective evaluation of carboplatin AUC dosing in patients with a BMI >27 or cachexia. Cancer Chemother Pharmacol 57 (2006) 241-247
44. Lin J., Knight E.L., Hogan M.L., and Singh A.K. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 14 (2003) 2573-2580
45. Calvert A.H., and Egorin M.J. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer 38 (2002) 11-16
46. Keevil B.G., Kilpatrick E.S., Nichols S.P., and Maylor P.W. Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. Clin Chem 44 (1998) 1535-1539
47. Hoppe A., Séronie-Vivien S., Thomas F., et al. Serum cystatin C is a better marker of topotecan clearance than serum creatinine. Clin Cancer Res 11 (2005) 3038-3044
48. Tonkin K.S., Levin L., and Powe J. Neither toxicity nor dose intensity of carboplatin is affected by glomerular filtration rate versus body surface area dose calculation in gynecologic malignancy. Int J Gynecol Cancer 4 (1994) 315-319
49. Ratain M.J., Schilsky R.L., Conley B.A., and Egorin M.J. Pharmacodynamics in cancer therapy. J Clin Oncol 8 (1990) 1739-1753
50. Thomson A. Why do therapeutic drug monitoring. Pharm J 273 (2004) 153-155
51. Oellerich M., and Armstrong V.W. Prodrug metabolites: implications for therapeutic drug monitoring. Clin Chem 47 (2001) 805-806
52. Hon Y.Y., and Evans W.E. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 44 (1998) 388-400
53. Bates D.W., Soldin S.J., Rainey P.M., and Micelli J.N. Strategies for physician education in therapeutic drug monitoring. Clin Chem 44 (1998) 401-407
54. Reyno L.M., Egorin M.J., Eisenberger M.A., Sinibaldi V.J., Zuhowski E.G., and Sridhara R. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13 (1995) 2187-2195
55. Lowis S.P., Price L., Pearson A.D.J., Newell D.R., and Cole M. A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. Br J Cancer 77 (1998) 2318-2323
56. Levitt N.C., Propper D.J., Madhusudan S., et al. Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. Br J Cancer 93 (2005) 60-69
57. Young A.M., Daryanani S., and Kerr D.J. Can pharmacokinetic monitoring improve clinical use of fluorouracil?. Clin Pharmacokinet 36 (1999) 391-398
58. Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol 47 (1999) 131-143
59. Fety R., Rolland F., Barberi-Heyob M., et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomised trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 4 (1998) 2039-2045
60. Rousseau A., and Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 16 (2002) 253-262
61. Evans W.E., Relling M.V., Rodman J.H., Crom W.R., Boyett J.M., and Pui C.-H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338 (1998) 499-505
62. Jelliffe R.W., Schumitzky A., Leary R., et al. Optimizing individualized dosage regimens of potentially toxic drugs. Applications of pharmacokinetic principles in drug development (2003), Kluwer Academic/Plenum Publishers, London 477-528
63. de Jongh F.E., Verweij J., Loos W.J., et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19 (2001) 3733-3739
64. Lowis S.P., Pearson A.D.J., Newell D.R., and Cole M. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer Res 53 (1993) 4881-4889
65. Eksborg S. Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). Acta Oncol 29 (1990) 339-342
66. Gusella M., Ferrazzi E., Ferrari M., and Padrini R. New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus. Ther Drug Monit 24 (2002) 425-431
67. Moore M.J., Bunting P., Yuan S., and Thiessen J.J. Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration. Ther Drug Monit 15 (1993) 394-399
68. Panday V.R., van Warmerdam L.J., Huizing M.T., Rodenhuis S., Schellens J.H., and Beijnen J.H. A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen. Cancer Chemother Pharmacol 43 (1999) 435-438
69. Hirth J., Watkins P.B., Strawderman M., Schott A., Bruno R., and Baker L.H. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6 (2000) 1255-1258
70. Milano G., Etienne M.C., Pierrefite V., Barberi-Heyob M., Deporte-Fety R., and Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79 (1999) 627-630
71. Milano G., and Etienne M.C. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Ther Drug Monit 18 (1996) 335-340
72. Lim W.-T., and McLeod H.L. Should screening for DPD deficiency be mandatory before 5-FU exposure?. Onkologie 27 (2004) 531-533
73. Grem J.L. Screening for dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 11 (2005) 5067-5068
74. Allegra C.J. Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?. Clin Cancer Res 5 (1999) 1947-1949
75. Gamelin E., Boisdron-Celle M., Guerin-Meyer V., et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17 (1999) 1105-1110
76. Chazal M., Etienne M.C., Renée N., Bourgeon A., Richelme H., and Milano G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 2 (1996) 507-510
77. Lu Z., Zhang R., and Diasio R.B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53 (1993) 5433-5438
78. Van Kuilenburg A.B.P., van Lenthe H., Blom M.J., Mul E.P.J., and Van Gennip A.H. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 79 (1999) 620-626
79. Fleming R.A., Milano G., Thyss A., et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52 (1992) 2899-2902
80. 13C-uracil breath test. Clin Cancer Res 10 (2004) 2652-2658
81. Remaud G., Boisdron-Celle M., Hameline C., Morel A., and Gamelin E. An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J Chromatogr B Analyt Technol Biomed Life Sci 823 (2005) 98-107
82. Relling M.V., Hancock M.L., Rivera G.K., et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91 (1999) 1983-1985
83. Black A.J., McLeod H.L., Capell H.A., et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129 (1998) 716-718
84. Ando Y., Saka H., Ando M., et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60 (2000) 6921-6926
85. Maitland M.L., Vasisht K., and Ratain M.J. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?. Trends Pharmacol Sci 27 (2006) 432-437
86. Henningsson A., Sparreboom A., Sandström M., et al. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 39 (2003) 1105-1114
87. Rivera E., Erder M.H., Fridman M., Frye D., and Hortobagyi G.N. First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study. Breast Cancer Res 5 (2003) R114-R120
88. Nieboer P., Vries E.G.E., Mulder N.H., and van der Graaf W.T.A. Relevance of high-dose chemotherapy in solid tumours. Cancer Treat Rev 31 (2005) 210-225
89. Alberts D.S., and Garcia D.J. Total platinum versus platinum dose intensification in ovarian cancer treatment. Semin Oncol 21 (1994) 11-15
90. Bergh J., Wiklund T., Erikstein B., et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomized trial. Lancet 356 (2000) 1384-1391
91. Hryniuk W. Dosage parameters in chemotherapy of breast cancer. Breast Dis 14 (2001) 21-30
92. Plumridge R., and Sewell G.J. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health Syst Pharm 58 (2001) 1760-1764
93. Baker J.P., and Jones S.E. Rationalisation of chemotherapy services in the University Hospital Birmingham NHS Trust. J Oncol Pharm Pract 4 (1998) 10-14
94. MacLean F., MacIntyre J., McDade J., and Moyes D. Dose banding of chemotherapy in the Edinburgh Cancer Centre. Pharm J 270 (2003) 691-693
95. Goffredo F. The role of the oncology pharmacist in 1999. J Oncol Pharm Pract 5 (1999) 140-142
96. Vincent C., Taylor-Adams S., Chapman E.J., et al. How to investigate and analyse clinical incidents: Clinical Risk Unit and Association of Litigation and Risk Management protocol. Br Med J 320 (2000) 777-781
97. Taxis K., and Barber N. Causes of intravenous medication errors: an ethnographic study. Qual Saf Health Care 12 (2003) 343-348
98. Taxis K., and Barber N. Ethnographic study of incidence and severity of intravenous drug errors. Br Med J 326 (2003) 684-687
99. Attilio R.M. Caring enough to understand: the road to oncology medication error prevention. Hosp Pharm 31 (1996) 17-26
100. Connor T.H., Sessink P.J.M., Harrison B.R., et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health-Syst Pharm 62 (2005) 475-484
101. Sewell G.J. Oncology pharmacy in the new millennium. J Oncol Pharm Pract 5 (1999) 143-144
102. Needle R. Putting a price on the service. Costing of the work of the pharmacy production unit. Hosp Pharm Pract 1 (1991) 55-57
103. Dooley M.J., Singh S., and Michael M. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer 12 (2004) 653-656
104. So J. Improving the lives of patients with cancer. Pharm Manage 18 (2002) 27-29
105. Goldspiel B.R. Global advances in oncology pharmacy practice. J Oncol Pharm Pract 1 (1995) 3-5
106. Heck G., Berger G., Kiemen U., and Latscha N. Aspects of quality management: accuracy in dosing antineoplastic drugs. J Oncol Pharm Practice 2 (1996) 29-34
107. Tran M. The impact of introducing pre-printed chemotherapy medication charts to a day chemotherapy unit. J Oncol Pharm Pract 6 (2000) 64-69
108. Kaestner S., Walker V., Roberts S., Perren T., and Sewell G. Clinical and pharmacokinetic (pk) study on "dose-banded" and individual-dose chemotherapy: an interim report. J Oncol Pharm Pract 10 (2004) 100
109. Xeloda®: Dose modification guidelines; Colorectal and breast cancer. Welwyn Garden City: Roche, 2002.
110. National Institute for Health and Clinical Excellence. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer. NICE Technology Appraisal 62. London: National Institute for Health and Clinical Excellence, 2003.
111. Ratain M.J. Dear doctor: We really are not sure what dose of capecitabine you should prescribe for your patient. J Clin Oncol 20 (2002) 1434-1435
112. Joint Formulary Committee. British National Formulary 50 (2005), British Medical Association and Royal Pharmaceutical Society of Great Britain, London
113. Van Ummersen L., Binger K., Volkman J., et al. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10 (2004) 7450-7456
114. Akbulut H., Tang Y., Maynard J., Zhang L., Pizzorno G., and Deisseroth A. Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms. Clin Cancer Res 10 (2004) 7738-7746